Jade Biosciences (JBIO) Q1 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on autoimmune diseases, with lead candidate JADE101 in Phase 1 and two additional programs, JADE201 and JADE301, in preclinical/early clinical stages.

• Interim Phase 1 data for JADE101 to be presented at the 63rd European Renal Association Congress; Phase 2 trial in IgA nephropathy patients set to begin in Q2 2026, with interim data expected in 2027.

• Phase 1 study of JADE201 for rheumatoid arthritis to start in Q2 2026, with interim data in 2027; JADE301 first-in-human trial planned for H1 2027.

• No product revenue to date; operations funded by equity and convertible note financings, including $205M in April 2025, $135M in October 2025, and $45M in December 2025.

• Leadership changes include the appointment of a new Chief Medical Officer and promotion of the President, R&D.

Financial highlights

• Cash, cash equivalents, and investments totaled $311.3M as of March 31, 2026, expected to fund operations into H1 2028.

• Research and development expenses rose to $36.1M in Q1 2026 from $20.0M in Q1 2025, driven by increased clinical and preclinical activity and personnel costs.

• General and administrative expenses increased to $7.4M in Q1 2026 from $3.4M in Q1 2025, reflecting higher personnel and public company costs.

• Net loss was $40.4M for Q1 2026, compared to $38.2M in Q1 2025.

• Shares outstanding as of March 31, 2026, were approximately 70.7M, including equivalents.

Outlook and guidance

• Cash runway projected into the first half of 2028 based on current operating plans.

• Interim data for JADE101 and JADE201 expected in 2027; Phase 2 trial for JADE101 and Phase 1 for JADE201 to begin in Q2 2026.

• JADE301 first-in-human trial expected in H1 2027, with further details to be disclosed in H2 2026.

• May require substantial additional funding for continued operations and growth.